✦ LIBER ✦

Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer

✍ Scribed by Doi, Toshihiko; Muro, Kei; Yoshino, Takayuki; Fuse, Nozomu; Ura, Takashi; Takahari, Daisuke; Feng, Hwa-ping; Shimamoto, Takashi; Noguchi, Kazuo; Ohtsu, Atsushi

Book ID: 121627325
Publisher: Springer
Year: 2013
Tongue: English
Weight: 517 KB
Volume: 72
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-013-2240-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 2 study of the insulin-like grow

A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors

✍ Diane L. Reidy-Lagunes; Efsevia Vakiani; Michal F. Segal; Ellen M. Hollywood; La 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 717 KB

A dose finding, safety and pharmacokinet

A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours

✍ Soria, Jean Charles; Massard, Christophe; Lazar, Vladimir; Ozoux, Marie-Laure; M 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 358 KB

Phase 1 study of ganitumab (AMG 479), a

Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors

✍ Haruyasu Murakami, Toshihiko Doi, Nobuyuki Yamamoto… 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 228 KB

Safety, Tolerability, Pharmacokinetics a

Safety, Tolerability, Pharmacokinetics and Antitumor Activity of Ganitumab, an Investigational Fully Human Monoclonal Antibody to Insulin-like Growth Factor Type 1 Receptor, Combined with Gemcitabine as First-line Therapy in Patients with Metastatic Pancreatic Cancer: A Phase 1b Study

✍ Okusaka, T.; Ikeda, M.; Fukutomi, A.; Kobayashi, Y.; Shibayama, K.; Takubo, T.; 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 157 KB

554 POSTER Pharmacokinetic (PK) and phar

554 POSTER Pharmacokinetic (PK) and pharmacodynamic (PD) results of Phase I studies of IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid malignancies

✍ M.L. Rothenberg; E. Poplin; P. LoRusso; E. Yu; J. Schwartz; F. Fox; J. Mehnert; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 73 KB

648 POSTER A phase I dose-escalation stu

648 POSTER A phase I dose-escalation study of weekly IMC-A12, a fully human insulin like growth factor-I receptor (IGF-IR) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer

✍ C. Higano; M. Gordon; P. LoRusso; F. Fox; T. Katz; J. Roecker; E. Rowinsky; H. Y 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 59 KB